{
 "disease": "small-intestine-cancer",
 "label": "Small intestine cancer",
 "url": "https://usebiotransfer.org/disease/small-intestine-cancer/",
 "built": "2026-09-12",
 "facts_hash": {
  "answers": "377d6d0c3946",
  "targets": "f01407e14657"
 },
 "sources": {
  "targets": "Open Targets Platform GraphQL API v4",
  "trials": "ClinicalTrials.gov API v2"
 },
 "retrieved": {
  "targets": "2026-09-12",
  "trials": "2026-09-12"
 },
 "query": {
  "endpoint": "https://clinicaltrials.gov/api/v2/studies",
  "shape": "query.cond=<disease>&query.intr=<term>&pageSize=200",
  "active_statuses": [
   "ACTIVE_NOT_RECRUITING",
   "ENROLLING_BY_INVITATION",
   "NOT_YET_RECRUITING",
   "RECRUITING"
  ],
  "dedup": "by NCT id across synonyms",
  "study_types": "interventional counted in headline; observational reported separately",
  "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search"
 },
 "targets": [
  {
   "symbol": "KRAS",
   "ensembl": "ENSG00000133703",
   "n_drug_entries": 3,
   "n_distinct_drugs": 3,
   "drugs": {
    "ADAGRASIB": "APPROVAL",
    "SALIRASIB": "PHASE_2",
    "SOTORASIB": "APPROVAL"
   },
   "approved": [
    "ADAGRASIB",
    "SOTORASIB"
   ],
   "n_approved": 2,
   "approved_for": {
    "ADAGRASIB": [
     "non-small cell lung carcinoma"
    ],
    "SOTORASIB": [
     "non-small cell lung carcinoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "TP53",
   "ensembl": "ENSG00000141510",
   "n_drug_entries": 9,
   "n_distinct_drugs": 8,
   "drugs": {
    "ALRIZOMADLIN": "PHASE_2",
    "CENERSEN": "PHASE_2",
    "CONTUSUGENE LADENOVEC": "PHASE_3",
    "EPRENETAPOPT": "PHASE_3",
    "IDASANUTLIN": "PHASE_3",
    "NAVTEMADLIN": "PHASE_3",
    "SIREMADLIN": "PHASE_2",
    "TEPRASIRAN": "PHASE_3"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "APC",
   "ensembl": "ENSG00000134982",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "SMAD4",
   "ensembl": "ENSG00000141646",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "ERBB2",
   "ensembl": "ENSG00000141736",
   "n_drug_entries": 48,
   "n_distinct_drugs": 45,
   "drugs": {
    "AC-480": "PHASE_2",
    "AEE-788": "PHASE_1_2",
    "AFATINIB": "APPROVAL",
    "AFATINIB DIMALEATE": "APPROVAL",
    "ALLITINIB": "PHASE_1",
    "ANVATABART OPADOTIN": "PHASE_2_3",
    "AV-412": "PHASE_1",
    "BMS-690514": "PHASE_2",
    "CANERTINIB": "PHASE_2",
    "CP-724714": "PHASE_2",
    "CUDC-101": "PHASE_1",
    "DACOMITINIB": "APPROVAL",
    "DISITAMAB VEDOTIN": "PHASE_3",
    "ERTUMAXOMAB": "PHASE_2",
    "GANCOTAMAB": "PHASE_2_3",
    "HEMAY-022": "PHASE_3",
    "JNJ-26483327": "PHASE_1",
    "KBP5209": "PHASE_1",
    "KN-026": "PHASE_3",
    "LAPATINIB": "APPROVAL",
    "LAPATINIB DITOSYLATE": "APPROVAL",
    "MARGETUXIMAB": "APPROVAL",
    "MASOPROCOL": "APPROVAL",
    "MM-111": "PHASE_2",
    "MUBRITINIB": "PHASE_1",
    "NERATINIB": "APPROVAL",
    "PERTUZUMAB": "APPROVAL",
    "POZIOTINIB": "PHASE_3",
    "PYROTINIB": "PHASE_3",
    "S-222611": "PHASE_1",
    "SAPITINIB": "PHASE_2",
    "TAK-285": "PHASE_1",
    "TARLOXOTINIB": "PHASE_2",
    "TESEVATINIB": "PHASE_3",
    "TRASTUZUMAB": "APPROVAL",
    "TRASTUZUMAB BOTIDOTIN": "PHASE_3",
    "TRASTUZUMAB DERUXTECAN": "APPROVAL",
    "TRASTUZUMAB DUOCARMAZINE": "APPROVAL",
    "TRASTUZUMAB EMTANSINE": "APPROVAL",
    "TUCATINIB": "APPROVAL",
    "TUXOBERTINIB": "PHASE_1_2",
    "VANDETANIB": "APPROVAL",
    "VARLITINIB": "PHASE_2_3",
    "ZANIDATAMAB": "APPROVAL",
    "ZENOCUTUZUMAB": "APPROVAL"
   },
   "approved": [
    "AFATINIB",
    "AFATINIB DIMALEATE",
    "DACOMITINIB",
    "LAPATINIB",
    "LAPATINIB DITOSYLATE",
    "MARGETUXIMAB",
    "MASOPROCOL",
    "NERATINIB",
    "PERTUZUMAB",
    "TRASTUZUMAB",
    "TRASTUZUMAB DERUXTECAN",
    "TRASTUZUMAB DUOCARMAZINE",
    "TRASTUZUMAB EMTANSINE",
    "TUCATINIB",
    "VANDETANIB",
    "ZANIDATAMAB",
    "ZENOCUTUZUMAB"
   ],
   "n_approved": 17,
   "approved_for": {
    "AFATINIB": [
     "non-small cell lung carcinoma"
    ],
    "AFATINIB DIMALEATE": [
     "non-small cell lung carcinoma"
    ],
    "DACOMITINIB": [
     "non-small cell lung carcinoma"
    ],
    "LAPATINIB": [
     "breast cancer"
    ],
    "LAPATINIB DITOSYLATE": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "MARGETUXIMAB": [
     "HER2 positive breast carcinoma",
     "breast cancer"
    ],
    "MASOPROCOL": [
     "prostate cancer"
    ],
    "NERATINIB": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "PERTUZUMAB": [
     "breast cancer",
     "breast carcinoma",
     "breast neoplasm"
    ],
    "TRASTUZUMAB": [
     "breast cancer",
     "breast carcinoma",
     "gastric cancer",
     "gastric neoplasm",
     "breast neoplasm"
    ],
    "TRASTUZUMAB DERUXTECAN": [
     "breast cancer",
     "HER2 positive breast carcinoma",
     "breast neoplasm"
    ],
    "TRASTUZUMAB DUOCARMAZINE": [],
    "TRASTUZUMAB EMTANSINE": [
     "breast cancer",
     "breast carcinoma",
     "breast neoplasm"
    ],
    "TUCATINIB": [
     "HER2 positive breast carcinoma",
     "metastasis",
     "breast neoplasm",
     "breast cancer",
     "colorectal carcinoma",
     "breast carcinoma"
    ],
    "VANDETANIB": [
     "thyroid gland carcinoma",
     "medullary thyroid gland carcinoma",
     "thyroid tumor"
    ],
    "ZANIDATAMAB": [
     "biliary tract neoplasm"
    ],
    "ZENOCUTUZUMAB": [
     "non-small cell lung carcinoma",
     "pancreatic neoplasm"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "BRAF",
   "ensembl": "ENSG00000157764",
   "n_drug_entries": 18,
   "n_distinct_drugs": 16,
   "drugs": {
    "ARQ-736": "PHASE_1",
    "BELVARAFENIB": "PHASE_2",
    "CEP-32496": "PHASE_1_2",
    "DABRAFENIB": "APPROVAL",
    "ENCORAFENIB": "APPROVAL",
    "LIFIRAFENIB": "PHASE_1_2",
    "LY-3009120": "PHASE_1",
    "NAPORAFENIB": "PHASE_3",
    "PLIXORAFENIB": "PHASE_2",
    "RAF-265": "PHASE_2",
    "REGORAFENIB": "APPROVAL",
    "RG-7256": "PHASE_1",
    "SORAFENIB": "APPROVAL",
    "TOVORAFENIB": "APPROVAL",
    "VEMURAFENIB": "APPROVAL",
    "XL-281": "PHASE_1_2"
   },
   "approved": [
    "DABRAFENIB",
    "ENCORAFENIB",
    "REGORAFENIB",
    "SORAFENIB",
    "TOVORAFENIB",
    "VEMURAFENIB"
   ],
   "n_approved": 6,
   "approved_for": {
    "DABRAFENIB": [
     "metastatic melanoma",
     "melanoma",
     "low grade glioma",
     "glioma"
    ],
    "ENCORAFENIB": [
     "melanoma",
     "colorectal neoplasm",
     "metastatic melanoma"
    ],
    "REGORAFENIB": [
     "colorectal cancer",
     "metastatic colorectal cancer",
     "colorectal neoplasm"
    ],
    "SORAFENIB": [
     "renal cell carcinoma",
     "hepatocellular carcinoma",
     "thyroid gland carcinoma"
    ],
    "TOVORAFENIB": [
     "glioma",
     "low grade glioma"
    ],
    "VEMURAFENIB": [
     "melanoma",
     "metastatic melanoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "KIT",
   "ensembl": "ENSG00000157404",
   "n_drug_entries": 38,
   "n_distinct_drugs": 33,
   "drugs": {
    "AMUVATINIB": "PHASE_2",
    "AVAPRITINIB": "APPROVAL",
    "BRIQUILIMAB": "PHASE_2",
    "CATEQUENTINIB": "PHASE_3",
    "CEDIRANIB": "APPROVAL",
    "CM-082": "PHASE_2",
    "DASATINIB": "APPROVAL",
    "DOVITINIB": "PHASE_3",
    "ENMD-2076": "PHASE_2",
    "FAMITINIB": "PHASE_3",
    "FORETINIB": "PHASE_2",
    "IMATINIB": "APPROVAL",
    "MASITINIB": "APPROVAL",
    "MIDOSTAURIN": "APPROVAL",
    "MOTESANIB": "PHASE_3",
    "OSI-930": "PHASE_1",
    "PAZOPANIB": "APPROVAL",
    "PEXIDARTINIB": "APPROVAL",
    "QUIZARTINIB": "APPROVAL",
    "REGORAFENIB": "APPROVAL",
    "RIPRETINIB": "APPROVAL",
    "SEMAXANIB": "PHASE_3",
    "SERALUTINIB": "PHASE_3",
    "SORAFENIB": "APPROVAL",
    "SU-014813": "PHASE_2",
    "SUNITINIB": "APPROVAL",
    "SUNITINIB MALATE": "APPROVAL",
    "TANDUTINIB": "PHASE_2",
    "TELATINIB": "PHASE_2",
    "TIVOZANIB": "APPROVAL",
    "VATALANIB": "PHASE_3",
    "XL-820": "PHASE_2",
    "XL-999": "PHASE_2"
   },
   "approved": [
    "AVAPRITINIB",
    "CEDIRANIB",
    "DASATINIB",
    "IMATINIB",
    "MASITINIB",
    "MIDOSTAURIN",
    "PAZOPANIB",
    "PEXIDARTINIB",
    "QUIZARTINIB",
    "REGORAFENIB",
    "RIPRETINIB",
    "SORAFENIB",
    "SUNITINIB",
    "SUNITINIB MALATE",
    "TIVOZANIB"
   ],
   "n_approved": 15,
   "approved_for": {
    "AVAPRITINIB": [
     "gastrointestinal stromal tumor"
    ],
    "CEDIRANIB": [],
    "DASATINIB": [
     "chronic myelogenous leukemia, BCR-ABL1 positive",
     "acute lymphoblastic leukemia",
     "blast phase chronic myelogenous leukemia, BCR-ABL1 positive",
     "lymphoid leukemia"
    ],
    "IMATINIB": [
     "chronic myelogenous leukemia, BCR-ABL1 positive",
     "myelodysplastic/myeloproliferative disease",
     "gastrointestinal stromal tumor",
     "dermatofibrosarcoma protuberans",
     "blast phase chronic myelogenous leukemia, BCR-ABL1 positive",
     "B-cell acute lymphoblastic leukemia",
     "hypereosinophilic syndrome"
    ],
    "MASITINIB": [],
    "MIDOSTAURIN": [
     "mast cell leukemia",
     "mastocytosis",
     "acute myeloid leukemia by FAB classification",
     "systemic mastocytosis",
     "acute myeloid leukemia"
    ],
    "PAZOPANIB": [
     "renal cell carcinoma",
     "soft tissue sarcoma",
     "sarcoma"
    ],
    "PEXIDARTINIB": [
     "tenosynovial giant cell tumor",
     "tenosynovial giant cell tumor, diffuse type"
    ],
    "QUIZARTINIB": [
     "acute myeloid leukemia by FAB classification"
    ],
    "REGORAFENIB": [
     "colorectal cancer",
     "metastatic colorectal cancer",
     "colorectal neoplasm"
    ],
    "RIPRETINIB": [
     "gastrointestinal stromal tumor"
    ],
    "SORAFENIB": [
     "renal cell carcinoma",
     "hepatocellular carcinoma",
     "thyroid gland carcinoma"
    ],
    "SUNITINIB": [
     "gastrointestinal stromal tumor",
     "renal cell carcinoma",
     "neuroendocrine neoplasm"
    ],
    "SUNITINIB MALATE": [
     "renal cell carcinoma",
     "gastrointestinal stromal tumor",
     "neuroendocrine neoplasm"
    ],
    "TIVOZANIB": [
     "renal cell carcinoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Phase 1 Clinical"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "PDGFRA",
   "ensembl": "ENSG00000134853",
   "n_drug_entries": 33,
   "n_distinct_drugs": 32,
   "drugs": {
    "AMUVATINIB": "PHASE_2",
    "AVAPRITINIB": "APPROVAL",
    "BECAPLERMIN": "APPROVAL",
    "CEDIRANIB": "APPROVAL",
    "CRENOLANIB": "PHASE_3",
    "DOVITINIB": "PHASE_3",
    "ENMD-981693": "PHASE_2",
    "FAMITINIB": "PHASE_3",
    "FORETINIB": "PHASE_2",
    "ILORASERTIB": "PHASE_2",
    "LINIFANIB": "PHASE_3",
    "MASITINIB": "APPROVAL",
    "MIDOSTAURIN": "APPROVAL",
    "MOTESANIB": "PHASE_3",
    "NINTEDANIB": "APPROVAL",
    "NINTEDANIB ESYLATE": "APPROVAL",
    "OLARATUMAB": "APPROVAL",
    "ORANTINIB": "PHASE_3",
    "PAZOPANIB": "APPROVAL",
    "QUIZARTINIB": "APPROVAL",
    "REGORAFENIB": "APPROVAL",
    "RIPRETINIB": "APPROVAL",
    "SERALUTINIB": "PHASE_3",
    "SU-014813": "PHASE_2",
    "SUNITINIB": "APPROVAL",
    "SUNITINIB MALATE": "APPROVAL",
    "TAK-593": "PHASE_1",
    "TOVETUMAB": "PHASE_2",
    "VATALANIB": "PHASE_3",
    "X-82": "PHASE_2",
    "XL-820": "PHASE_2",
    "XL-999": "PHASE_2"
   },
   "approved": [
    "AVAPRITINIB",
    "BECAPLERMIN",
    "CEDIRANIB",
    "MASITINIB",
    "MIDOSTAURIN",
    "NINTEDANIB",
    "NINTEDANIB ESYLATE",
    "OLARATUMAB",
    "PAZOPANIB",
    "QUIZARTINIB",
    "REGORAFENIB",
    "RIPRETINIB",
    "SUNITINIB",
    "SUNITINIB MALATE"
   ],
   "n_approved": 14,
   "approved_for": {
    "AVAPRITINIB": [
     "gastrointestinal stromal tumor"
    ],
    "BECAPLERMIN": [
     "Skin ulcer"
    ],
    "CEDIRANIB": [],
    "MASITINIB": [],
    "MIDOSTAURIN": [
     "mast cell leukemia",
     "mastocytosis",
     "acute myeloid leukemia by FAB classification",
     "systemic mastocytosis",
     "acute myeloid leukemia"
    ],
    "NINTEDANIB": [
     "idiopathic pulmonary fibrosis",
     "colorectal cancer",
     "interstitial lung disease",
     "systemic sclerosis",
     "pulmonary fibrosis"
    ],
    "NINTEDANIB ESYLATE": [
     "idiopathic pulmonary fibrosis",
     "systemic sclerosis",
     "non-small cell lung carcinoma",
     "Interstitial pneumonitis"
    ],
    "OLARATUMAB": [
     "sarcoma",
     "soft tissue sarcoma"
    ],
    "PAZOPANIB": [
     "renal cell carcinoma",
     "soft tissue sarcoma",
     "sarcoma"
    ],
    "QUIZARTINIB": [
     "acute myeloid leukemia by FAB classification"
    ],
    "REGORAFENIB": [
     "colorectal cancer",
     "metastatic colorectal cancer",
     "colorectal neoplasm"
    ],
    "RIPRETINIB": [
     "gastrointestinal stromal tumor"
    ],
    "SUNITINIB": [
     "gastrointestinal stromal tumor",
     "renal cell carcinoma",
     "neuroendocrine neoplasm"
    ],
    "SUNITINIB MALATE": [
     "renal cell carcinoma",
     "gastrointestinal stromal tumor",
     "neuroendocrine neoplasm"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "MEN1",
   "ensembl": "ENSG00000133895",
   "n_drug_entries": 3,
   "n_distinct_drugs": 2,
   "drugs": {
    "REVUMENIB": "APPROVAL",
    "REVUMENIB SESQUIFUMARATE": "PHASE_1_2"
   },
   "approved": [
    "REVUMENIB"
   ],
   "n_approved": 1,
   "approved_for": {
    "REVUMENIB": [
     "leukemia"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Phase 1 Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "CDKN1B",
   "ensembl": "ENSG00000111276",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "SSTR2",
   "ensembl": "ENSG00000180616",
   "n_drug_entries": 14,
   "n_distinct_drugs": 12,
   "drugs": {
    "LANREOTIDE": "APPROVAL",
    "LUTETIUM OXODOTREOTIDE": "PHASE_3",
    "LUTETIUM OXODOTREOTIDE LU-177": "APPROVAL",
    "OCTREOTIDE": "APPROVAL",
    "ONZIGOLIDE": "PHASE_3",
    "PALTUSOTINE": "APPROVAL",
    "PASIREOTIDE": "APPROVAL",
    "PASIREOTIDE DIASPARTATE": "PHASE_2",
    "PASIREOTIDE PAMOATE": "APPROVAL",
    "SOMATOSTATIN": "PHASE_3",
    "VAPREOTIDE": "PHASE_3",
    "VELDOREOTIDE": "PHASE_2"
   },
   "approved": [
    "LANREOTIDE",
    "LUTETIUM OXODOTREOTIDE LU-177",
    "OCTREOTIDE",
    "PALTUSOTINE",
    "PASIREOTIDE",
    "PASIREOTIDE PAMOATE"
   ],
   "n_approved": 6,
   "approved_for": {
    "LANREOTIDE": [
     "acromegaly",
     "carcinoid syndrome"
    ],
    "LUTETIUM OXODOTREOTIDE LU-177": [
     "neuroendocrine neoplasm",
     "neuroendocrine carcinoma"
    ],
    "OCTREOTIDE": [
     "carcinoid tumor",
     "acromegaly",
     "metastasis"
    ],
    "PALTUSOTINE": [
     "acromegaly"
    ],
    "PASIREOTIDE": [
     "acromegaly",
     "ACTH-dependent Cushing syndrome"
    ],
    "PASIREOTIDE PAMOATE": [
     "acromegaly"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "MTOR",
   "ensembl": "ENSG00000198793",
   "n_drug_entries": 26,
   "n_distinct_drugs": 25,
   "drugs": {
    "APITOLISIB": "PHASE_2",
    "AZD-8055": "PHASE_1_2",
    "BGT-226": "PHASE_1_2",
    "CC-115": "PHASE_2",
    "DACTOLISIB": "PHASE_3",
    "DS-3078A": "PHASE_1",
    "DS-7423": "PHASE_1",
    "GEDATOLISIB": "PHASE_3",
    "INDOXIMOD": "PHASE_2_3",
    "OMIPALISIB": "PHASE_1",
    "ONATASERTIB": "PHASE_2",
    "OSI-027": "PHASE_2",
    "PALOMID-529": "PHASE_1",
    "PANULISIB": "PHASE_1",
    "PERHEXILINE": "APPROVAL",
    "PF-04691502": "PHASE_2",
    "PKI-179": "PHASE_1",
    "RG-7603": "PHASE_1",
    "RIDAFOROLIMUS": "APPROVAL",
    "SAMOTOLISIB": "PHASE_2",
    "SAPANISERTIB": "PHASE_2",
    "SF-1126": "PHASE_2",
    "VISTUSERTIB": "PHASE_2",
    "VOXTALISIB": "PHASE_2",
    "VS-5584": "PHASE_1"
   },
   "approved": [
    "PERHEXILINE",
    "RIDAFOROLIMUS"
   ],
   "n_approved": 2,
   "approved_for": {
    "PERHEXILINE": [
     "cardiovascular disorder",
     "angina pectoris"
    ],
    "RIDAFOROLIMUS": []
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  }
 ],
 "trials": {
  "by_antigen": {
   "SSTR2": {
    "n": 4,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT00004895",
      "title": "Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2012-06-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01578239",
      "title": "A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours",
      "status": "COMPLETED",
      "last_update": "2022-04-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03057509",
      "title": "A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors",
      "status": "WITHDRAWN",
      "last_update": "2019-06-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04065165",
      "title": "Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome",
      "status": "WITHDRAWN",
      "last_update": "2020-02-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "SSTR2",
     "somatostatin receptor",
     "octreotide",
     "lanreotide",
     "lutetium Lu 177 dotatate",
     "Lutathera",
     "dotatate"
    ]
   },
   "PD-1": {
    "n": 125,
    "n_observational": 7,
    "n_active": 59,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT04282044",
      "title": "Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies",
      "status": "RECRUITING",
      "last_update": "2024-02-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04585750",
      "title": "The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04701476",
      "title": "TATE and Pembrolizumab (MK3475) in mCRC and NSCLC",
      "status": "RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05086692",
      "title": "A Beta-only IL-2 ImmunoTherapY Study",
      "status": "RECRUITING",
      "last_update": "2025-07-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05176483",
      "title": "Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05272709",
      "title": "TT-702 in Patients With Advanced Solid Tumours.",
      "status": "RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05492682",
      "title": "START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer",
      "status": "RECRUITING",
      "last_update": "2026-05-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05856981",
      "title": "Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-12-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06265285",
      "title": "Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program",
      "status": "RECRUITING",
      "last_update": "2026-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06270706",
      "title": "A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06281678",
      "title": "A Study of IBI363 in Subjects with Advanced Solid Malignancies",
      "status": "RECRUITING",
      "last_update": "2024-12-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06333314",
      "title": "Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI",
      "status": "RECRUITING",
      "last_update": "2025-12-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06362369",
      "title": "A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy",
      "status": "RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06400472",
      "title": "A Study of Sofe-M in Participants With Selected Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06638931",
      "title": "Agnostic Therapy in Rare Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06764771",
      "title": "A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06789172",
      "title": "A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06835569",
      "title": "A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations",
      "status": "RECRUITING",
      "last_update": "2026-06-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06917079",
      "title": "BBO-11818 in Adult Subjects With KRAS Mutant Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06983743",
      "title": "A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07020221",
      "title": "A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07094113",
      "title": "AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07223047",
      "title": "A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-05-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07223424",
      "title": "Patient Preference for Subcutaneous vs. Intravenous Immune Therapy",
      "status": "RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07227168",
      "title": "A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07334119",
      "title": "Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07376707",
      "title": "A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-01-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07623369",
      "title": "A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07749586",
      "title": "A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00441337",
      "title": "A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies",
      "status": "COMPLETED",
      "last_update": "2015-02-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02009449",
      "title": "A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-07-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02346955",
      "title": "Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)",
      "status": "TERMINATED",
      "last_update": "2020-08-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02423954",
      "title": "Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)",
      "status": "TERMINATED",
      "last_update": "2018-07-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02432963",
      "title": "Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02628067",
      "title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02713529",
      "title": "Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer",
      "status": "COMPLETED",
      "last_update": "2023-01-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02817633",
      "title": "A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02834013",
      "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02886897",
      "title": "A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2016-09-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02890069",
      "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat",
      "status": "COMPLETED",
      "last_update": "2023-01-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02949219",
      "title": "Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery",
      "status": "UNKNOWN",
      "last_update": "2024-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02952989",
      "title": "A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2019-07-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02983045",
      "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-03-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03085914",
      "title": "A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)",
      "status": "COMPLETED",
      "last_update": "2022-09-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03126110",
      "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-08-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03170960",
      "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03190174",
      "title": "Nivolumab (Opdivo\u00ae) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers",
      "status": "COMPLETED",
      "last_update": "2025-02-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03228667",
      "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03329950",
      "title": "A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-03-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03361228",
      "title": "A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2020-05-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03454451",
      "title": "CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers",
      "status": "COMPLETED",
      "last_update": "2023-12-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03485209",
      "title": "Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03621982",
      "title": "Study of ADCT-301 in Patients With Selected Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-06-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03629756",
      "title": "A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-05-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03639714",
      "title": "A Study of a Personalized Neoantigen Cancer Vaccine",
      "status": "COMPLETED",
      "last_update": "2023-09-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03656627",
      "title": "Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease",
      "status": "TERMINATED",
      "last_update": "2023-02-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03761017",
      "title": "MGD019 DART\u00ae Protein in Unresectable/Metastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2025-03-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03761914",
      "title": "Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers",
      "status": "COMPLETED",
      "last_update": "2024-11-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03811652",
      "title": "A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2019-12-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03829436",
      "title": "TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers",
      "status": "COMPLETED",
      "last_update": "2023-07-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03841110",
      "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03849469",
      "title": "A Study of XmAb\u00ae22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-03-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03894618",
      "title": "SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas",
      "status": "COMPLETED",
      "last_update": "2025-04-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03948763",
      "title": "A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)",
      "status": "TERMINATED",
      "last_update": "2025-01-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03953235",
      "title": "A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens",
      "status": "COMPLETED",
      "last_update": "2023-09-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03970382",
      "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors",
      "status": "SUSPENDED",
      "last_update": "2022-08-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04000529",
      "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies",
      "status": "TERMINATED",
      "last_update": "2025-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04083599",
      "title": "GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04140526",
      "title": "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-05-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04234113",
      "title": "Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-03-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04244552",
      "title": "A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies",
      "status": "TERMINATED",
      "last_update": "2023-12-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04256707",
      "title": "Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment",
      "status": "COMPLETED",
      "last_update": "2025-03-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04272034",
      "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-10-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04278144",
      "title": "A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-09-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04306900",
      "title": "TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers",
      "status": "COMPLETED",
      "last_update": "2025-07-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04333004",
      "title": "Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy",
      "status": "UNKNOWN",
      "last_update": "2020-04-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04344795",
      "title": "Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-09-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04432857",
      "title": "AN0025 and Pembrolizumab Combination in Advanced Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2024-06-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04458259",
      "title": "Study of PF-07265807 in Participants With Metastatic Solid Tumors.",
      "status": "TERMINATED",
      "last_update": "2026-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04460456",
      "title": "A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2022-06-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04579757",
      "title": "Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-05-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04580485",
      "title": "INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-07-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04606472",
      "title": "A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04628780",
      "title": "Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-07-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04660929",
      "title": "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2024-12-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04672434",
      "title": "Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-12-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04699188",
      "title": "Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04708470",
      "title": "A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04729322",
      "title": "Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04802876",
      "title": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04913337",
      "title": "Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies",
      "status": "UNKNOWN",
      "last_update": "2024-10-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04956640",
      "title": "Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05008861",
      "title": "Gut Microbiota Reconstruction for NSCLC Immunotherapy",
      "status": "UNKNOWN",
      "last_update": "2021-08-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05061537",
      "title": "Study of PF-07263689 in Participants With Selected Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-04-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05215574",
      "title": "Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05256381",
      "title": "A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05311618",
      "title": "Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2024-04-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05395052",
      "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05544929",
      "title": "A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05576077",
      "title": "A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-03-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05582031",
      "title": "Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers",
      "status": "WITHDRAWN",
      "last_update": "2023-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05585034",
      "title": "Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb\u00ae808 in Combination With Pembrolizumab in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-08-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05620134",
      "title": "Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05651022",
      "title": "Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05704985",
      "title": "Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-05-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05787587",
      "title": "A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05788484",
      "title": "A Study of CDX-585 in Patients With Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-06-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05789069",
      "title": "A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05858736",
      "title": "Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05872867",
      "title": "Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)",
      "status": "UNKNOWN",
      "last_update": "2024-03-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05886075",
      "title": "A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2023-06-02",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06084689",
      "title": "Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures",
      "status": "WITHDRAWN",
      "last_update": "2025-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06131398",
      "title": "A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-08-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06285097",
      "title": "A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-09-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06447662",
      "title": "A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06448364",
      "title": "A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination",
      "status": "TERMINATED",
      "last_update": "2024-11-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06544655",
      "title": "A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06546553",
      "title": "A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.",
      "status": "TERMINATED",
      "last_update": "2026-02-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06580938",
      "title": "A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer",
      "status": "TERMINATED",
      "last_update": "2026-03-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06607185",
      "title": "A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06704724",
      "title": "A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.",
      "status": "TERMINATED",
      "last_update": "2026-05-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07576725",
      "title": "Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07623642",
      "title": "A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07807345",
      "title": "Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 2,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT02983045",
       "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors",
       "status": "COMPLETED",
       "last_update": "2023-03-13",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03970382",
       "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors",
       "status": "SUSPENDED",
       "last_update": "2022-08-18",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "PD-1",
     "pembrolizumab",
     "nivolumab"
    ]
   },
   "KIT": {
    "n": 4,
    "n_observational": 4,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00006357",
      "title": "STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma",
      "status": "COMPLETED",
      "last_update": "2012-09-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00025415",
      "title": "Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction",
      "status": "COMPLETED",
      "last_update": "2013-02-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02777710",
      "title": "Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers",
      "status": "COMPLETED",
      "last_update": "2021-09-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05348187",
      "title": "Clinical Performance Study Protocol for Therascreen\u00ae KRAS RGQ PCR Kit",
      "status": "COMPLETED",
      "last_update": "2024-11-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "KIT",
     "imatinib",
     "ripretinib",
     "avapritinib"
    ]
   },
   "HER2": {
    "n": 34,
    "n_observational": 5,
    "n_active": 13,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT05969041",
      "title": "Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors",
      "status": "RECRUITING",
      "last_update": "2024-01-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06625775",
      "title": "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06695845",
      "title": "A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06715839",
      "title": "Target-specific immunoPET Imaging of Digestive System Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-12-31",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07192068",
      "title": "Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.",
      "status": "RECRUITING",
      "last_update": "2025-12-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07216105",
      "title": "FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07334119",
      "title": "Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07540572",
      "title": "A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-06-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07630961",
      "title": "Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004074",
      "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu",
      "status": "COMPLETED",
      "last_update": "2013-02-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005842",
      "title": "Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2013-02-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00031681",
      "title": "7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)",
      "status": "COMPLETED",
      "last_update": "2013-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02442414",
      "title": "A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2022-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02900664",
      "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris\u00ae (Canakinumab) or Mekinist\u00ae (Trametinib)",
      "status": "COMPLETED",
      "last_update": "2022-03-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02983045",
      "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-03-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03319459",
      "title": "FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2021-11-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03821233",
      "title": "A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers",
      "status": "COMPLETED",
      "last_update": "2025-01-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03924466",
      "title": "Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients",
      "status": "UNKNOWN",
      "last_update": "2024-02-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03970382",
      "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors",
      "status": "SUSPENDED",
      "last_update": "2022-08-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04042480",
      "title": "A Study of SGN-CD228A in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-03-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04209465",
      "title": "A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.",
      "status": "TERMINATED",
      "last_update": "2025-04-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04278144",
      "title": "A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-09-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04319757",
      "title": "ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-12-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04460456",
      "title": "A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2022-06-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04464967",
      "title": "Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers",
      "status": "WITHDRAWN",
      "last_update": "2021-05-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04579380",
      "title": "Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04644068",
      "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04660929",
      "title": "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2024-12-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04665921",
      "title": "A Study of SGN-STNV in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-02-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05091528",
      "title": "A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers",
      "status": "TERMINATED",
      "last_update": "2022-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05395052",
      "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05576077",
      "title": "A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-03-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07036185",
      "title": "A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07631884",
      "title": "Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 2,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT02983045",
       "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors",
       "status": "COMPLETED",
       "last_update": "2023-03-13",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03970382",
       "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors",
       "status": "SUSPENDED",
       "last_update": "2022-08-18",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "HER2",
     "ERBB2",
     "trastuzumab"
    ]
   },
   "EGFR": {
    "n": 80,
    "n_observational": 5,
    "n_active": 40,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT03175224",
      "title": "APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-06-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04930432",
      "title": "Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-02-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05786924",
      "title": "Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06179160",
      "title": "A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06385925",
      "title": "A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation",
      "status": "RECRUITING",
      "last_update": "2026-04-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06586515",
      "title": "MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06621563",
      "title": "Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-04-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06682793",
      "title": "A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression",
      "status": "RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06715839",
      "title": "Target-specific immunoPET Imaging of Digestive System Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-12-31",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06764771",
      "title": "A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06835569",
      "title": "A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations",
      "status": "RECRUITING",
      "last_update": "2026-06-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06917079",
      "title": "BBO-11818 in Adult Subjects With KRAS Mutant Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06983743",
      "title": "A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07020221",
      "title": "A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07085091",
      "title": "A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-05-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07094113",
      "title": "AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07094204",
      "title": "A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07216105",
      "title": "FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07223047",
      "title": "A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-05-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07300150",
      "title": "A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07349537",
      "title": "Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07397338",
      "title": "Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07468071",
      "title": "Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07589205",
      "title": "Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004879",
      "title": "Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer",
      "status": "COMPLETED",
      "last_update": "2013-01-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101348",
      "title": "Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer",
      "status": "COMPLETED",
      "last_update": "2014-06-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00397384",
      "title": "Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2015-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00425204",
      "title": "Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment",
      "status": "COMPLETED",
      "last_update": "2008-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00622674",
      "title": "Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2017-12-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00820417",
      "title": "Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib",
      "status": "COMPLETED",
      "last_update": "2009-01-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00910676",
      "title": "Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors",
      "status": "COMPLETED",
      "last_update": "2012-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01166035",
      "title": "Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2010-07-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01202409",
      "title": "CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater",
      "status": "COMPLETED",
      "last_update": "2020-02-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01451632",
      "title": "A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers",
      "status": "COMPLETED",
      "last_update": "2016-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01520389",
      "title": "Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment",
      "status": "COMPLETED",
      "last_update": "2018-03-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01815749",
      "title": "Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02284139",
      "title": "Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects",
      "status": "COMPLETED",
      "last_update": "2018-04-23",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02365662",
      "title": "A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor",
      "status": "TERMINATED",
      "last_update": "2018-03-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02442414",
      "title": "A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2022-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02538627",
      "title": "Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib",
      "status": "TERMINATED",
      "last_update": "2017-09-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02729298",
      "title": "First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-11-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02857270",
      "title": "A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2022-11-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02900664",
      "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris\u00ae (Canakinumab) or Mekinist\u00ae (Trametinib)",
      "status": "COMPLETED",
      "last_update": "2022-03-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03170960",
      "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03319459",
      "title": "FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2021-11-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03421912",
      "title": "Satisfaction and Quality of Life Comparison Between Patients Using Cicaplast Baume B5 Versus Dexeryl for the Management of Cutaneous Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors (iEGFR)",
      "status": "COMPLETED",
      "last_update": "2021-07-09",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03518554",
      "title": "A First in Human, Dose Escalation Study of JAB-3068 \uff08SHP2 Inhibitor\uff09 in Adult Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-12-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03565003",
      "title": "A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China",
      "status": "COMPLETED",
      "last_update": "2024-09-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03811652",
      "title": "A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2019-12-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03989115",
      "title": "Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC",
      "status": "COMPLETED",
      "last_update": "2023-06-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04045496",
      "title": "A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-12-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04121286",
      "title": "A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China",
      "status": "COMPLETED",
      "last_update": "2025-05-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04165031",
      "title": "A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation",
      "status": "TERMINATED",
      "last_update": "2021-11-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04209465",
      "title": "A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.",
      "status": "TERMINATED",
      "last_update": "2025-04-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04449874",
      "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04464967",
      "title": "Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers",
      "status": "WITHDRAWN",
      "last_update": "2021-05-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04603287",
      "title": "A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04800822",
      "title": "PF-07284892 in Participants With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04844073",
      "title": "A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer",
      "status": "TERMINATED",
      "last_update": "2025-12-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04868877",
      "title": "Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04878692",
      "title": "Evaluation of a Cosmetic Product to Preserve Skin Conditions When Using Anti-EGFR Cancer Therapies",
      "status": "UNKNOWN",
      "last_update": "2021-05-07",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04956640",
      "title": "Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05084859",
      "title": "A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-08-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05099549",
      "title": "Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers",
      "status": "TERMINATED",
      "last_update": "2024-03-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05163028",
      "title": "A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05194995",
      "title": "JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05358249",
      "title": "Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05395052",
      "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05578092",
      "title": "A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway",
      "status": "TERMINATED",
      "last_update": "2026-02-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05704985",
      "title": "Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-05-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05954871",
      "title": "Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-11-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06024174",
      "title": "A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-07-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06147037",
      "title": "A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06447662",
      "title": "A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06599502",
      "title": "A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation",
      "status": "TERMINATED",
      "last_update": "2026-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06607185",
      "title": "A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06704724",
      "title": "A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.",
      "status": "TERMINATED",
      "last_update": "2026-05-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07551778",
      "title": "Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07807956",
      "title": "A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 2,
     "n_observational": 0,
     "n_active": 2,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT06682793",
       "title": "A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression",
       "status": "RECRUITING",
       "last_update": "2025-09-09",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07551778",
       "title": "Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-08-26",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "EGFR",
     "cetuximab",
     "panitumumab"
    ]
   },
   "VEGF": {
    "n": 30,
    "n_observational": 7,
    "n_active": 14,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04999761",
      "title": "AB122 Platform Study",
      "status": "RECRUITING",
      "last_update": "2026-08-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06131840",
      "title": "A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06400472",
      "title": "A Study of Sofe-M in Participants With Selected Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06625775",
      "title": "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06839105",
      "title": "A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07623369",
      "title": "A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101348",
      "title": "Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer",
      "status": "COMPLETED",
      "last_update": "2014-06-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00458731",
      "title": "Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma",
      "status": "COMPLETED",
      "last_update": "2014-02-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00734890",
      "title": "Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma",
      "status": "COMPLETED",
      "last_update": "2012-03-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01208103",
      "title": "Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma",
      "status": "COMPLETED",
      "last_update": "2020-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01327612",
      "title": "Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)",
      "status": "COMPLETED",
      "last_update": "2021-02-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01676714",
      "title": "Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2018-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01803282",
      "title": "Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2020-06-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03597581",
      "title": "A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-04-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04164069",
      "title": "Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab",
      "status": "COMPLETED",
      "last_update": "2024-12-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04449874",
      "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04553692",
      "title": "Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers",
      "status": "TERMINATED",
      "last_update": "2025-03-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04579679",
      "title": "Open-Label Surufatinib in European Patients With NET",
      "status": "TERMINATED",
      "last_update": "2025-07-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04579757",
      "title": "Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-05-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05029882",
      "title": "Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05110118",
      "title": "Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects",
      "status": "COMPLETED",
      "last_update": "2021-11-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05647122",
      "title": "First in Human Study of AZD9592 in Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05800418",
      "title": "Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza \u00ae in Healthy Male Volunteers",
      "status": "COMPLETED",
      "last_update": "2023-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06447662",
      "title": "A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06448364",
      "title": "A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination",
      "status": "TERMINATED",
      "last_update": "2024-11-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06704724",
      "title": "A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.",
      "status": "TERMINATED",
      "last_update": "2026-05-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06724263",
      "title": "A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-12-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06730750",
      "title": "A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07551778",
      "title": "Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 1,
     "n_observational": 0,
     "n_active": 1,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT07551778",
       "title": "Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-08-26",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "VEGF",
     "bevacizumab"
    ]
   }
  },
  "by_drug": {
   "ADAGRASIB": {
    "n": 8,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT06026410",
      "title": "KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06764771",
      "title": "A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04330664",
      "title": "Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)",
      "status": "COMPLETED",
      "last_update": "2025-04-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04975256",
      "title": "Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)",
      "status": "TERMINATED",
      "last_update": "2024-12-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05578092",
      "title": "A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway",
      "status": "TERMINATED",
      "last_update": "2026-02-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05848843",
      "title": "A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations",
      "status": "WITHDRAWN",
      "last_update": "2024-01-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06024174",
      "title": "A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-07-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06039384",
      "title": "A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation",
      "status": "TERMINATED",
      "last_update": "2026-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AFATINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02450656",
      "title": "Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer",
      "status": "UNKNOWN",
      "last_update": "2018-08-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AFATINIB DIMALEATE": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02450656",
      "title": "Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer",
      "status": "UNKNOWN",
      "last_update": "2018-08-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CEDIRANIB": {
    "n": 5,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00107250",
      "title": "AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)",
      "status": "COMPLETED",
      "last_update": "2023-08-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00343408",
      "title": "AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2023-08-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00458731",
      "title": "Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma",
      "status": "COMPLETED",
      "last_update": "2014-02-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00937482",
      "title": "Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer",
      "status": "TERMINATED",
      "last_update": "2013-03-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01131234",
      "title": "Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2014-12-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DABRAFENIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT07440290",
      "title": "DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02034110",
      "title": "Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers",
      "status": "COMPLETED",
      "last_update": "2023-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DACOMITINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02039336",
      "title": "Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC",
      "status": "COMPLETED",
      "last_update": "2025-07-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DASATINIB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00608361",
      "title": "Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2015-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01609816",
      "title": "Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2020-03-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01643603",
      "title": "Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies",
      "status": "TERMINATED",
      "last_update": "2020-12-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04164069",
      "title": "Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab",
      "status": "COMPLETED",
      "last_update": "2024-12-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DOVITINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01676714",
      "title": "Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2018-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ENCORAFENIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02857270",
      "title": "A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2022-11-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04800822",
      "title": "PF-07284892 in Participants With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "IMATINIB": {
    "n": 2,
    "n_observational": 1,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00006357",
      "title": "STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma",
      "status": "COMPLETED",
      "last_update": "2012-09-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00025415",
      "title": "Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction",
      "status": "COMPLETED",
      "last_update": "2013-02-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "KBP5209": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02442414",
      "title": "A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2022-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LANREOTIDE": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT04065165",
      "title": "Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome",
      "status": "WITHDRAWN",
      "last_update": "2020-02-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LAPATINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02230553",
      "title": "Lapatinib Plus Trametinib in KRAS Mutant NSCLC",
      "status": "COMPLETED",
      "last_update": "2025-07-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LAPATINIB DITOSYLATE": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02230553",
      "title": "Lapatinib Plus Trametinib in KRAS Mutant NSCLC",
      "status": "COMPLETED",
      "last_update": "2025-07-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LUTETIUM OXODOTREOTIDE": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01578239",
      "title": "A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours",
      "status": "COMPLETED",
      "last_update": "2022-04-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LUTETIUM OXODOTREOTIDE LU-177": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01578239",
      "title": "A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours",
      "status": "COMPLETED",
      "last_update": "2022-04-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LY-3009120": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02014116",
      "title": "A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body",
      "status": "TERMINATED",
      "last_update": "2019-12-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "MOTESANIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01273090",
      "title": "Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-01-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NAPORAFENIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05907304",
      "title": "A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OCTREOTIDE": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT00004895",
      "title": "Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2012-06-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01578239",
      "title": "A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours",
      "status": "COMPLETED",
      "last_update": "2022-04-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03057509",
      "title": "A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors",
      "status": "WITHDRAWN",
      "last_update": "2019-06-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ORANTINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00024063",
      "title": "SU006668 in Treating Patients With Advanced Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2013-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OSI-930": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00513851",
      "title": "Phase 1 Study of OSI-930 in Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2011-09-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PASIREOTIDE": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01253161",
      "title": "Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)",
      "status": "COMPLETED",
      "last_update": "2023-03-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01434069",
      "title": "Phase I Trial of Combination of FOLFIRI and SOM 230",
      "status": "COMPLETED",
      "last_update": "2015-12-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PAZOPANIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02009449",
      "title": "A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-07-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PEXIDARTINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02777710",
      "title": "Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers",
      "status": "COMPLETED",
      "last_update": "2021-09-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "REGORAFENIB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT04701476",
      "title": "TATE and Pembrolizumab (MK3475) in mCRC and NSCLC",
      "status": "RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05582031",
      "title": "Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers",
      "status": "WITHDRAWN",
      "last_update": "2023-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SIREMADLIN": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02890069",
      "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat",
      "status": "COMPLETED",
      "last_update": "2023-01-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SOMATOSTATIN": {
    "n": 4,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 3,
    "trials": [
     {
      "nct": "NCT01578239",
      "title": "A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours",
      "status": "COMPLETED",
      "last_update": "2022-04-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03057509",
      "title": "A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors",
      "status": "WITHDRAWN",
      "last_update": "2019-06-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04065165",
      "title": "Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome",
      "status": "WITHDRAWN",
      "last_update": "2020-02-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04672876",
      "title": "Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors",
      "status": "WITHDRAWN",
      "last_update": "2021-12-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SORAFENIB": {
    "n": 0,
    "n_observational": 1,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": []
   },
   "SUNITINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00474994",
      "title": "Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas",
      "status": "COMPLETED",
      "last_update": "2016-01-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SUNITINIB MALATE": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00474994",
      "title": "Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas",
      "status": "COMPLETED",
      "last_update": "2016-01-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TOVORAFENIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04985604",
      "title": "Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-10-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07121829",
      "title": "Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-08-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TRASTUZUMAB": {
    "n": 12,
    "n_observational": 1,
    "n_active": 5,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT06625775",
      "title": "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07216105",
      "title": "FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004074",
      "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu",
      "status": "COMPLETED",
      "last_update": "2013-02-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005842",
      "title": "Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2013-02-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03319459",
      "title": "FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2021-11-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04278144",
      "title": "A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-09-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04464967",
      "title": "Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers",
      "status": "WITHDRAWN",
      "last_update": "2021-05-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04579380",
      "title": "Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04644068",
      "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05091528",
      "title": "A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers",
      "status": "TERMINATED",
      "last_update": "2022-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05395052",
      "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07631884",
      "title": "Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TRASTUZUMAB DERUXTECAN": {
    "n": 2,
    "n_observational": 1,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04644068",
      "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05091528",
      "title": "A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers",
      "status": "TERMINATED",
      "last_update": "2022-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TUCATINIB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04579380",
      "title": "Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05091528",
      "title": "A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers",
      "status": "TERMINATED",
      "last_update": "2022-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07768358",
      "title": "Tucatinib Continuation Study",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VANDETANIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00734890",
      "title": "Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma",
      "status": "COMPLETED",
      "last_update": "2012-03-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VEMURAFENIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05768178",
      "title": "DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.",
      "status": "RECRUITING",
      "last_update": "2025-11-24",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VOXTALISIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01390818",
      "title": "Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2017-03-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "XL-281": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00451880",
      "title": "Study of XL281 in Adults With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2011-10-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ZANIDATAMAB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06695845",
      "title": "A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07192068",
      "title": "Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.",
      "status": "RECRUITING",
      "last_update": "2025-12-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ZENOCUTUZUMAB": {
    "n": 0,
    "n_observational": 1,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": []
   }
  }
 }
}